A Near-Term Post Mortem
Executive Summary
With the divestiture of its sales force to Watson Pharmaceuticals, CoCensys has officially announced the death of its near-term commercialization program--and less officially, but probably no less definitively, stopped any one else from implementing a similar strategy.